ASIA BEAT: US faces hurdles as TPP talks intensify
This article was originally published in Scrip
Talks on the Trans-Pacific Partnership (TPP) have been going on for around three years, but the public is little wiser now on what's being discussed than when they first started. In the history of free trade agreements, never has so little been known about so much by so many.
You may also be interested in...
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.